Sign in

CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company

SELLAS Life Sciences Group, Inc.

Sign in to watch
Ticker
SLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
6462005278
Business address
7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
Former names
GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
  1. 4 Derivatives Options or other derivatives
  2. 3 Insider Initial Statement of Ownership
  3. 4 Other acquisition EVP, Chief Operating Officer acquired 2,461 shares (other)
  4. 4 Other acquisition EVP, Chief Medical Officer acquired 2,461 shares (other)
  5. 4 Other acquisition VP, Chief Financial Officer acquired 2,461 shares (other)
  6. 4 Other acquisition President & CEO acquired 2,461 shares (other)
  7. 4 Derivatives Options or other derivatives
  8. 4 Open-market sale Director sold 150,000 shares at $5.92 ($888,540)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Open-market buy Director bought 20,000 shares at $4.94 ($98,742)
  11. 4 Open-market sale Director sold 187,500 shares at $4.33 ($812,438)
  12. 4 Open-market sale Director sold 300,000 shares at $4.18 ($1,253,040)
  13. 4 Open-market sale Director sold 75,000 shares at an average $5.58 ($418,755)
  14. 4 Open-market sale EVP & Chief Operating Officer sold 100,000 shares at $5.57 ($556,500)
  15. 4 Open-market sale Director sold 250,000 shares at $5.41 ($1,352,500)
  16. 4 Open-market sale Director sold 250,000 shares at $5.28 ($1,320,000)
  17. 4 Open-market sale President & CEO sold 796,765 shares at $4.83 ($3,848,375)
  18. 4/A Derivatives Options or other derivatives
  19. 4 Other acquisition President & CEO acquired 5,656 shares (other)
  20. 4 Other acquisition EVP & Chief Operating Officer acquired 5,656 shares (other)

Page 11 of 22 · 436 filings